Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tisagenlecleucel in Chinese Adults with R/R DLBCL
NCT04456023Phase 2Withdrawn
- Sponsor
- Novartis
- Start
- Jan 2022
- Primary completion
- Oct 2022
- Modality
- CAR-T Cells
01
Overview
A Phase 2 trial of tisagenlecleucel in diffuse large B-cell lymphoma (DLBCL), sponsored by Novartis. Planned start Jan 2022; status: withdrawn.
02
Drugs
tisagenlecleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04456023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04456023.